CRISPR zaps HPV in cervical lesions: first human test begins
NCT ID NCT07170254
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up by 36 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRISPR/Cas9 gene therapy (BD114VLP or BD114) injected directly into cervical lesions
What this could lead to
If successful, this could point toward a one-time gene-editing treatment to clear HPV-16-related high-grade cervical lesions without surgery.
What could go wrong
This is a very early, small trial with only 12 participants, so results may not apply broadly. Gene editing carries unknown long-term risks, and the therapy may not effectively clear lesions or HPV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, 200090, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact